Author

Benno Mbeya

Observed name: B Mbeya

Institution: Ifakara Health Institute

Observed institution: Ifakara Health Institute

OpenAlex ID: A5092096596

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

2023 · A Dierig, M Hoelscher, et al. · Trials · 17

Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials

2023 · Emmanuel Musisi, Adam Wyness, et al. · The Lancet Microbe · 11

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)

2026 · Hamu J. Mlyuka, Alphonce Liyoyo, et al. · Trials

Works count: 5

Citation count: 63

H-index: 4

I10-index: 3